-
FDA Approves Gazyva for Pediatric Patients with Idiopathic Nephrotic Syndrome
A New Treatment Option for Children The U.S. Food and Drug Administration (FDA) has officially approved Gazyva (obinutuzumab) for the treatment of adult and pediatric patients aged 2 years and older with idiopathic nephrotic syndrome (specifically steroid-sensitive nephrotic syndrome, steroid-dependent nephrotic syndrome, and steroid-resistant nephrotic syndrome). This milestone marks a significant step forward for families…
-
A New Treatment Option: FDA Approves Stelara for Pediatric Ulcerative Colitis
Expanding Care for Young Patients Managing ulcerative colitis as a child or teenager presents unique challenges. Recently, the medical community reached a significant milestone in pediatric care. The FDA has officially approved Stelara (ustekinumab) for the treatment of pediatric patients aged 6 years and older who are suffering from moderately to severely active ulcerative colitis.…
-
New Hope for Pediatric Patients: FDA Approves Linzess for Functional Constipation
NASDAQ: $IRWD A Significant Milestone for Pediatric Digestive Health Managing digestive health in children can be a challenging experience for both parents and medical providers. Recently, the FDA reached a significant milestone in pediatric care by approving the use of Linzess (linaclotide) for the treatment of functional constipation (FC) in patients aged two years and…
-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…